- Gadolinium-based contrast media
- Iodinated contrast media
- Barium-based contrast media
- Microbubble contrast media
Contrast Media Market size was valued at USD 5.2 billion in 2022 and expected to reach a value of USD 6.1 billion by 2029, witnessing a CAGR of 3.8% during the forecast period 2023-2029. Contrast media are the agents used in the medical imaging techniques for improving the contrast of structures or fluids in the body to help the better image of anatomical structures. Contrast media are commonly used in the various imaging techniques such as Computerized Tomography (CT), X-ray, MRI scans, and ultrasound techniques. The most commonly used contrast media are iodine and gadolinium-containing contrast media. Increase in the prevalence of cardiovascular, neurological, cancer, and other chronic diseases, a rise in technological advancements in Contrast Media Market such as syringeless power injectors, and growing usage of MRI, CT, and echocardiogram in a diagnosis of various diseases are anticipated to fuel the contrast media market over the forecast period. Moreover, approvals of the novel contrast agents, a rise in the public-private partnership for establishing diagnostic centres, product pipeline (In May 2016, Dotarem sponsored by Guerbet is in Phase 3 clinical trials), an increase in R&D activities for developing various contrasting agents also expected to boost the contrast media market. However, the adverse effects associated with the contrast media, lower adoption in underdeveloped economies, and lack of reimbursement policies are the factors hindering the growth of contrast media market.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Contrast media market is growing at a significant CAGR owing to increase in the prevalence of chronic diseases and upsurge in the adoption of various diagnostic techniques such as CT, MRI, X-ray and ultrasound in the wide range of applications. Companies are focusing on the R&D activities for the development of newer contrast agents for improving the contrast of the images. Acquisitions and mergers, product approvals, and product launchings are the strategies followed by the companies for increasing their revenue. For instance, in May 2016, FDA approved the Gadavist injection manufactured by Bayer used with magnetic resonance angiography of the supra-aortic artery. Moreover, in 2015, Guerbet has acquired Mallinckrodt’s contrast media and delivery systems for the diversification of business segment.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Disclaimer The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.